Wegovy Shows 5-Fold Stronger NAION Signal Than Ozempic in 30 Million FDA Reports
Updated
Updated · Medical Daily · Jul 13
Wegovy Shows 5-Fold Stronger NAION Signal Than Ozempic in 30 Million FDA Reports
1 articles · Updated · Medical Daily · Jul 13
Summary
A British Journal of Ophthalmology analysis of more than 30 million FDA adverse-event reports found Wegovy had a nearly five times stronger safety signal for NAION than Ozempic, with all three semaglutide products showing a signal.
NAION is a rare "eye stroke" that can cause sudden, often permanent vision loss in one eye, and researchers said Wegovy’s higher 2.4 mg weekly dose versus Ozempic’s 2 mg may help explain the stronger pattern.
The FAERS-based study does not prove Wegovy causes NAION or show true incidence, because voluntary reports can be skewed by media attention, prescribing patterns and patients’ underlying risks.
Men showed a more pronounced signal, and researchers said risk may be concentrated in patients with sleep apnea, diabetes, cardiovascular disease or a structurally vulnerable optic disc.
The FDA has not issued a label change or safety alert, but the authors called for urgent prospective studies as millions of Americans use Wegovy and other GLP-1 drugs.
Is the blockbuster weight-loss drug Wegovy trading obesity for a risk of irreversible vision loss?
Why did Europe warn of Wegovy's 'eye stroke' risk over a year ago while the US FDA remains silent?
With scientists divided on the link to blindness, why do over 140 lawsuits already cite it as key evidence?
Wegovy and NAION: Quantifying a Tenfold Increased Risk of Vision Loss with Semaglutide
Overview
Recent studies have identified a safety signal linking Wegovy, a GLP-1 receptor agonist, to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), based on comprehensive reviews of FDA adverse event reports. Unlike tirzepatide, which does not show this risk, Wegovy’s strong GLP-1 stimulation and rapid weight loss effects may specifically contribute to NAION. Researchers suggest that tirzepatide’s dual receptor activity and gradual dosing lead to more moderate GLP-1 pathway stimulation, possibly reducing such side effects. This highlights the importance of understanding how different drugs in the same class can have distinct safety profiles.